Navigation Links
Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results

BASKING RIDGE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) a leader in the development of targeted products in the Clinical and Sports Nutrition Market, announces financial results for the third quarter ended September 30, 2008.

Net revenue for the third quarter of 2008 increased 660% to $780,423 compared to $90,339 in the third quarter 2007. The Company reduced its' reported net loss of ($1,342,300), or ($0.01) per share, compared to a net loss of ($2,952,953) or a net loss of ($0.03) per share, during the same period last year. The improved third quarter 2008 financial performance can be attributed to increased revenues generated from the initial sale of the Company's new Ready-to-Drink line of Resurgex(R) products and the Company's pricing power in an otherwise challenging economy.

Revenues increased to $1,317,906 during the nine month period ended September 30, 2008, as compared to $472,318 in the prior year period, representing an increase of 179%. Net loss decreased for nine months ended September 30, 2008 to ($7,681,685) or a loss of $(0.05) per share compared to a net loss of ($9,142,665), or a net loss of ($0.11) per share during the comparable prior period. The decrease in net loss is due to increased revenue and gross profits coupled with a new focus on controlling operational expenses.

According to the recently appointed Chief Executive Officer, Mark Mirken, "We are extremely pleased at the initial reaction to the commercialization of our new Ready-to-Drink Resurgex(R) product lines. We believe that these products and future line extensions will continue to drive our revenues going forward." Mr. Mirken went on to state, "As we prepare for 2009, the Company will focus on cost containment as well as new revenue opportunities by introducing exciting line extensions of the Company's proprietary Resurgex(R) and Surgex(R) products. Through our addition of distribution and development relationships we anticipate the growth of our revenues and profitability in 2009."

About Millennium

Millennium's six marketed products form its advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, caloric dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Millennium's technology, opportunities for the Millennium, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of Millennium's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Millennium's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ('SEC'). Millennium Biotechnologies, Inc.

SOURCE Millennium Biotechnologies Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
8. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
9. Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference
10. Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc.
11. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
Post Your Comments:
(Date:11/25/2015)... Canadian, OK (PRWEB) , ... November 25, 2015 , ... ... and International training center for the Narconon network, announced the release of a new ... Since 1966 the Narconon organization has been working with drug- and alcohol-addicted individuals with ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 ... Tri Lite’s personal heating products business. Cozy Products explains what this means for ... fit in well with the Cozy Products business model: to sell personal heaters that ...
(Date:11/25/2015)... Calif. (PRWEB) , ... November 25, 2015 , ... Beddit® ... and Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ ... and understand how well you slept. The SleepScore is created by a proprietary algorithm. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... “While riding the ... inventor, from Bronx, N.Y. “I thought there had to be a convenient and comfortable ... PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or inclement ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for ... The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology: